NEWS
SELLAS Life Sciences Announces Positive Recommendation from the Independent Data Monitoring Committee of the Phase 3 REGAL Trial in Acute Myeloid Leukemia
SELLAS Life Sciences (NASDAQ: SLS) announced a positive recommendation from the Independent Data Monitoring Committee (IDMC) for its Phase 3 REGAL trial in acute myeloid leukemia (AML). The IDMC advised the trial to continue without modifications, citing no safety or futility concerns. The IDMC's review of unblinded data indicated a high level of confidence that an interim analysis will occur by Q4 2024. This recommendation strengthens SELLAS' confidence in GPS (galinpepimut-S) as a potential AML treatment. The REGAL trial targets AML patients in complete remission post-second-line salvage therapy, with the primary endpoint being overall survival.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1075Followers
68Following
7409Visitors
Follow
Traders Cap Ayam : But why the price is going down?
Jaguar8 OP Traders Cap Ayam : Shorts
Traders Cap Ayam Jaguar8 OP : Such a waste